International Journal of Drug Policy
Volume 21, Issue 2 , Pages 119-121, March 2010

Implementing harm reduction for heroin users in Afghanistan, the worldwide opium supplier

  • Olivier Maguet

      Affiliations

    • Médecins du Monde Harm Reduction Programme Responsible in Kabul, Afghanistan
    • Corresponding Author InformationCorresponding author.
  • ,
  • Murtaza Majeed

      Affiliations

    • Médecins du Monde Harm Reduction Training and Resource Centre Officer in Kabul, Afghanistan

Received 17 October 2009; received in revised form 8 January 2010; accepted 8 January 2010. published online 22 February 2010.

Abstract 

Afghanistan has suffered decades of war, occupation and unrest. It is also the world's greatest producer of opium and drug production and trafficking account for a third of the total Afghan economy. Currently alongside the “War on Terrorism”, the control and eradication of opium production and related trafficking is a main concern of the international community. However, this focus on supply reduction has meant scant attention has been paid to increasing drug use problems within the country; it is estimated there are up to 25,000 opium users and 20,000 heroin users in Kabul city. Drug use is often a response to war, poverty and under-development, however, street opium and heroin manufactured in the country are widely available, affordable and of high purity. This paper documents the efforts of non-governmental organisations to promote and develop harm reduction and treatment services for problem drug users in Afghanistan in this difficult context.

Keywords: Afghanistan, Harm reduction, Opium production, Heroin use, Drug control policy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0955-3959(10)00007-1

doi:10.1016/j.drugpo.2010.01.006

International Journal of Drug Policy
Volume 21, Issue 2 , Pages 119-121, March 2010